Press Releases

Gilead Board of Directors Approves Two-for-One Stock Split

"This stock split, our second in two years, reflects our continued financial success and the confidence we have in the long-term growth opportunities for our company," said John C. Martin, Ph.D., President and Chief Executive Officer, Gilead Sciences. "With five marketed products, our portfolio is stronger than ever, and through this stock split, we expect to further increase the liquidity and market interest in Gilead Sciences."

Stockholders who hold their stock in a brokerage account will receive their new shares through their broker. Stockholders who maintain physical possession of their stock certificates will have their additional shares mailed or delivered on or about March 7, 2002, by the company's transfer agent, Mellon Investor Services L.L.C. The company's stock will begin trading at the post-split price on Friday, March 8, 2002. Any shares purchased between February 15 and March 8 will come with a "due-bill" entitling the buyer to one additional share for each share purchased.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

For more information on Gilead Sciences, please visit the company's Web site at or call the Gilead Corporate Communications Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT:          Gilead Sciences, Inc.
                  Susan Hubbard, 650/522-5715 (Investors)
                  Amy Flood, 650/522-5643 (Media)

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire.  All rights reserved.